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Over the past several years, the prevalence of human 
disease  caused  by  nontuberculous  mycobacteria  (NTM) 
has increased. Whether the increase in cases is real or 
whether more cases are being recognized remains unclear. 
Despite a considerable increase in knowledge about NTM 
infections, they still represent a diagnostic and therapeutic 
challenge for several reasons: 1) pathogenic isolates may 
be indistinguishable from contaminant or saprophytic iso-
lates; 2) timely and reliable identification of isolates may 
depend on proper communication between clinicians and 
laboratory staff; 3) lack of standardized susceptibility test-
ing makes adoption of tailored therapies unrealistic; and 4) 
lack of treatment guidelines exposes patients to toxic drugs 
and disappointing outcomes. Laboratory research and mul-
ticenter controlled trials are needed to improve diagnosis 
and treatment of these infections.
T
he >120 recognized species of nontuberculous myco-
bacteria (NTM) share common features: 1) they are 
facultative  pathogens;  2)  evidence  of  human-to-human 
transmission is lacking; 3) some NTM species are ubiqui-
tous and others have more restricted distribution; 4) treat-
ment may be difficult and vary according to the involved 
organism and disease site; and 5) pathogenesis is still un-
defined, depending on the interaction between the micro-
organism and the host’s immune system (1). About 90% 
of cases involve the pulmonary system; the rest involve 
lymph nodes, skin, soft tissues, and bones. Less frequently 
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reported are central nervous system disease, keratitis, and 
otitis media (1,2). We reviewed the epidemiology, clini-
cal features, diagnosis, and treatment of the most common 
extrapulmonary diseases associated with NTM in immuno-
competent persons (2–5).
Lymphadenitis
Localized lymphadenitis most commonly affects chil-
dren; peak incidence occurs at 1–5 years of age (6). The 
route of infection is hypothesized to be by way of the lym-
phatic vessels that drain the mouth and pharynx. The most 
frequently isolated species is Mycobacterium avium com-
plex (MAC), followed by M. scrofulaceum, M. malmoense, 
and M. hemophilum (7). However, a growing number of 
previously unrecognized slow-growing mycobacteria have 
been implicated with increasing frequency in reports of iso-
lated or microclustered cases (Table 1) (8).
Generally, NTM adenitis is an indolent disease; most 
patients are otherwise healthy and have as their sole clini-
cal sign a chronic neck mass that does not respond to an-
timicrobial drug therapy. The disease is usually unilateral 
and occurs in the cervical, submandibular, or preauricular 
lymph nodes, although parotid and postauricular node in-
volvement has been reported. The nodes enlarge and may 
rapidly soften and rupture, forming a draining sinus. Al-
though spontaneous regression has occasionally been de-
scribed, healing usually occurs by fibrosis and calcification. 
Pyogenic and tuberculous adenitis are the most important 
differential diagnoses.
Although a presumptive diagnosis of nontuberculous 
mycobacterial adenitis can be made on the basis of clini-
cal history and physical examination, definitive diagnosis 
depends upon the recovery of mycobacteria. Every effort 
should be made to obtain material for culture and further 
identification. Cultures of draining and ulcerated lesions, es-
pecially when swabs are used for specimen sampling, have 
been shown to give a lower diagnostic yield than do needle 
aspirates (9) or tissue biopsy samples. For recovery of NTM, 
use of a liquid medium or radiometric growth detection are 
regarded as the standard. Moreover, in children who have 
not been vaccinated with M. bovis BCG, purified protein 
derivative skin testing may be used as a surrogate test to di-
agnose chronic cervicofacial lymphadenitis (10). Histologic 
appearance of necrotizing granulomatous inflammation with 
various degrees of caseation is also diagnostic.
Treatment  of  uncomplicated  NTM  lymphadenitis  is 
complete surgical excision. Incision and drainage are dis-
couraged because they usually lead to sinus tract formation 
with chronic discharge. In a recent well-designed trial in-
cluding 100 children with culture- or PCR-confirmed diag-
noses, surgery was more effective than chemotherapy; cure 
rates were 96% and 66%, respectively (11). Total excision 
should be performed as early as possible to maximize re-
covery of the causative agent, to prevent further cosmetic 
damage,  to  prevent  extensive  spread  and  subsequently 
more difficult excision, and to cure disease. For some pa-
tients, however, surgery is associated with substantial risk 
either because of a discharging sinus or proximity of facial 
nerve branches. For these patients, chemotherapy preceded 
by a diagnostic biopsy sample is recommended. Chemo-
therapy should also be considered for patients in whom 
lymphadenitis recurs after surgery or for whom all abnor-
mal tissue could not be excised. Recent data indicate fine-
needle aspiration as the preferred diagnostic technique for 
patients with nontuberculous mycobacterial adenitis who 
do not undergo surgical excision. The optimal chemothera-
peutic regimen and its duration are still undetermined, but 
combination therapy including clarithromycin and a rifa-
mycin, either rifampin or rifabutin and/or ethambutol, may 
be beneficial.
Osteoarticular Infections
NTM infections involving the musculoskeletal system 
are uncommon. However, when they do occur, both rapid- 
and slow-growing species have been implicated in chronic 
granulomatous infections involving tendon sheaths, bursae, 
bones, and joints. These are usually acquired by direct in-
oculation of the pathogen from an environmental source or 
a contiguous infection focus as a consequence of surgical 
procedures, penetrating trauma, injuries, or needle injec-
tions. Most affected patients are immunocompetent, but 
some mycobacterial species, such as M. chelonae and M. 
hemophilum, are almost entirely recovered from patients 
with  serious  underlying  diseases  (HIV  infection,  immu-
nosuppressive therapy, or blood disorders) (4). In a recent 
study  of  vertebral  osteomyelitis  caused  by  NTM  (12), 
various degrees of immunosuppression were found in 17 
(51.5%) of 33 patients. From the 31 patients with spinal 
infection studied, the following NTM species were recov-
ered: MAC (n = 13), M. xenopi (n = 7), M. fortuitum (n = 
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Table 1. Less frequently encountered mycobacterial species 
recovered from immunocompetent persons with lymphadenitis* 
Mycobacterium sp. 
No. cases 
reported  Identification method 
M. bohemicum 3 GS
M. celatum 1 RH, HPLC, GS
M. genavense 1 RH, GS
M. heckeshornense 1 GS
M. heidelbergense 1 GS
M. interjectum 4 GS
M. lentiflavum 5 HPLC, GS
M. palustre 1 GS
M. parmense 1 HPLC, GS
M. simiae 4 RH, HPLC, GS
M. triplex 4 GS
M. tusciae 1 HPLC, GS
*Most persons were children. GS, gene sequencing; RH, reverse 
hybridization; HPLC, high-performance liquid chromatography. Extrapulmonary Infections and NTM
5), M. abscessus (n = 3), M. kansasii (n = 1), M. simiae (n = 
1), and unidentified NTM species (n = 1). M. hemophilum 
also causes NTM osteomyelitis infections in bone marrow 
and solid organ transplants (13). The hand and wrist are the 
most frequently reported sites of NTM tenosynovitis be-
cause of their abundance of synovial fluid and tissue com-
bined with a higher probability of penetrating injury. Most 
frequently, M. marinum and M. kansasii are involved; less 
frequently, M. avium complex, M. szulgai, M. terrae, M. 
fortuitum, M. chelonae, M. abscessus, M. malmoense, and 
M. xenopi are found (14).
Clinically, osteoarticular infections caused by NTM are 
indistinguishable from tuberculosis-associated infections. 
Signs and symptoms such as localized pain (with or without 
neurologic impairment), joint stiffness and swelling, low-
grade fever, sweating, chills, anorexia, malaise, and weight 
loss have been reported (Table 2). On rare occasions, sup-
puration followed by extensive necrosis of the synovial tis-
sue may occur (3), although in more severe cases infection 
may extend to the periosteum and lead to osteomyelitis (3). 
The clinical course of the disease is typically protracted; 
average time from onset of symptoms to diagnosis may be 
as long as 10 months. To prevent severe tissue destruction 
and neurologic disorders, prompt and accurate diagnosis is 
essential. Diagnosis relies on clinical suspicion and must 
be considered for patients with increasing musculoskeletal 
system signs, those with inflammation after penetrating or 
blunt trauma, and those with underlying risk factors who 
undergo a medical procedure. Culture of synovial fluid and 
tissue biopsy are mandatory for definitive diagnosis and 
identification of the causative agent. Computed tomogra-
phy and sonography may help guide percutaneous tissue 
biopsy sampling of infected areas or diagnostic aspiration 
of  intraarticular  fluid  (15).  Histopathologic  examination 
has shown a spectrum of inflammatory changes, including 
granulomatous lesions with or without caseation (3).
Lack of the following have greatly limited develop-
ment of consensus guidelines for the treatment of mus-
culoskeletal  infections  caused  by  NTM:  correlation  be-
tween in vitro susceptibility testing and clinical outcome, 
standardized  antimicrobial-drug susceptibility  testing  for 
most NTM species, and clinical trials comparing differ-
ent therapeutic regimens among an adequate number of 
patients. Prolonged chemotherapy with an isolate-tailored 
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Table 2. Clinical signs associated with osteoarticular infections caused by nontuberculous mycobacteria 
Disease Affected site Mycobacterium spp. 
Underlying diseases and risk factors  





M. malmoense Rheumatoid arthritis (1) 
Arthritis Knee, ankle M. xenopi None* (6), invasive medical procedure (1) 
Arthritis Multiple joints: wrist, knee, 
finger, ankle, elbow, 
vertebrae, shoulder 
M. kansasii AIDS (13), rheumatoid arthritis (3), systemic lupus 
erythematous (2), renal transplant (2), polymyositis (1), 
progressive systemic sclerosis (1), myelodysplasia (1), 
none (26), localized trauma (10), steroid therapy (10) 
Arthritis Knee M. kansasii Prosthetic joint (1) 
Synovitis (carpal 
tunnel syndrome) 
Wrist   M. szulgai No underlying disease, fish-tank cleaning (2) 
Tenosynovitis  Hand M. intracellulare None* (1) 
Tenosynovitis  Hand M. chelonae Penetrating injury (2), fracture (1), 
Immunosuppression (3)  
Tenosynovitis  Hand, wrist M. avium complex  Steroid injection (1), trauma (8), surgery (4) 
Osteomyelitis  Sternum, foot, elbow   M. wolinsky Cardiac surgery (1), stepped on nail (1), open fracture (1)
Osteomyelitis  Femur, tibia, calcaneus, 
toe, elbow, sternum 
M. goodii Open fracture (4), stepped on nail (1), surgery (2), 
penetrating trauma (2), puncture wound (1) 
Osteomyelitis  Wrist  M. scrofulaceum Diabetes (1) 
Osteomyelitis  Hand, ankle, wrist  M. marinum Fisherman exposed to aquarium (25), trauma (1), local 
or systemic steroids (20) 
Osteomyelitis  M. ulcerans Traumatic injury (213) 
Osteomyelitis  Vertebrae  M. avium complex,  
M. xenopi, M. fortuitum, 
M. abscessus, M. kansasii, 
M. simiae
Systemic lupus erythematous and treatment with 
steroids (7), AIDS (4), interferon receptor defect (3), 
carcinoma (1), renal failure (1), chronic granulomatous 
disease (1), none* (16)
Osteomyelitis  Vertebrae  M. xenopi Vertebral disk surgery (58) 
Osteomyelitis  Tibia M. conceptionense Fracture (1) 
Osteomyelitis  Vertebrae  M. abscessus Trauma to the back (1) 
Osteomyelitis  Vertebrae  M. avium complex Trauma to the back (1) 
Osteomyelitis  Lower extremity, upper 
extremity, vertebrae, 
disseminated disease 
M. hemophilum AIDS (21), bone marrow or solid organ transplant (7); 
AIDS plus solid organ transplant (1),  
lymphoma (2), polycythemia vera (1) 
*Otherwise healthy with no underlying disease or risk factor. SYNOPSIS
drug combination associated with surgical debridement is 
currently recommended for all musculoskeletal infections, 
especially in patients with abscesses (12).
Skin and Soft Tissue Infections
Skin and soft tissue infections usually occur after trau-
matic injury, surgery, or cosmetic procedures, which may 
expose a wound to soil, water, or medical devices occa-
sionally contaminated with environmental mycobacteria. 
Although the epidemiology and clinical presentations of 
NTM responsible for skin and soft tissue infections differ, 
some species (MAC, M. kansasii, M. xenopi, and M. mari-
num) have been reported worldwide, whereas others (M. 
ulcerans) have limited geographic distribution.
M. marinum causes diseases in many fish species and 
is distributed worldwide. It is an opportunistic pathogen of 
humans, in whom infection is infrequent and occurs by di-
rect injury from fish fins or bites or after cutaneous trauma 
and subsequent exposure to contaminated water or other 
sources of infection (shrimp, shellfish, frogs, turtles, dol-
phin, eels, and oysters). An increasing number of cases have 
been reported from most countries with temperate climates 
(1). Predisposing occupations and activities include fish-
ery worker, seafood handler, fish-tank owner, fisherman, 
pet shop worker, and water-related recreational exposure 
(4). Consistent with the organism’s growth at low tempera-
tures, M. marinum infections are usually limited to the skin 
and confined, with few exceptions, to 1 extremity. For fish-
tank owners, disease is often located in the hand or fingers; 
for those who swim in pools, the elbow is affected for 85%, 
followed by knee and foot (16). The incubation period is 
usually <4 weeks but can be as long as 9 months. Signs and 
symptoms of early infection are nonspecific, e.g., swelling 
and pain followed by >1 skin lesions (17). At the inocula-
tion site, an erythematous or bluish papulonodular lesion 
(≈0.5–3 cm) develops and slowly enlarges, becoming more 
tender until it suppurates (18) (Figure). In ≈33% of patients, 
M. marinum infection may spread to deeper structures (soft 
tissues, tendons, and bone) (19), leading to extensive scar-
ring and varying degrees of functional impairment. Less 
frequently, the disease extends from the inoculation site to 
regional lymph nodes along the lymphatic vessels, mim-
icking the clinical appearance of cutaneous sporotrichosis 
(20). Key elements for diagnosis of M. marinum infection 
are a history of exposure to potential sources of infection; 
a histopathologic appearance of granulomatous inflamma-
tion but no caseation; and culture growth of M. marinum, 
which strongly depends on incubation temperature. For lo-
calized skin lesions without a history of exposure to fish 
tanks, swimming pools, or tropical fish, other NTM must 
be considered (21).
Although  presumptive  identification  can  rely  on  a 
few biochemical and phenotypic tests such as production 
of photochromogenic pigment, negative nitrate reduction, 
and positive tests for urease and Tween 80 hydrolysis, de-
finitive identification involves reverse hybridization tech-
niques, or, alternatively, high-performance liquid chroma-
tography analysis of mycolic acids and DNA sequencing 
assays  (22,23).  In  vitro  susceptibility  test  results  of  M. 
marinum clinical isolates have been reported extensively in 
the literature. Only clarithromycin, minocycline, and ami-
kacin  provide  complete  coverage  (100%  susceptibility); 
doxycycline, rifampin, and trimethoprim/sulfamethoxazole 
encounter different degrees of resistance (24). Drug-sus-
ceptibility testing of M. marinum isolates is recommended 
only for patients who remain culture positive after several 
months of therapy (25). Although a standardized regimen 
for M. marinum disease is still undefined, monotherapy with 
doxycycline, minocycline, trimethoprim/sulfamethoxazole, 
or clarithromycin should be limited to patients with mild 
disease only. Clarithromycin combined with ethambutol or 
rifampin is likely the best combination therapy. Treatment 
with 2 agents should be continued for at least 1–2 months 
after resolution of skin lesions. In addition, surgical treat-
ment (from mild debridement to amputation) may be re-
quired, especially when deep structures are involved (2).
M. ulcerans is the causative agent of Buruli ulcer, a 
disease reported in >30 countries, mainly in tropical and 
subtropical regions of Western and Central Africa but also 
in  Central  and  South  America,  Southeast  Asia,  and  the 
Western Pacific region (26). Currently limited knowledge 
is mainly the result of a low number of reported cases and 
inadequate surveillance. Recently, however, studies con-
ducted in some areas in which M. ulcerans is highly en-
demic have reported infection rates higher than those for 
either tuberculosis or leprosy (27). Epidemiologic data on 
detection of M. ulcerans DNA in aquatic insects (e.g., or-
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Figure. Mycobacterium marinum infection of the arm of a fish-tank 
worker.Extrapulmonary Infections and NTM
ders Odonata and Coleoptera) and snails, as well as in the 
biofilm of aquatic plants, strongly suggest that the organism 
is associated with exposure to surface water involved in 
environmental changes such as mining, deforestation, ag-
riculture, and hydraulic installations and that it is likely to 
occupy a specific niche within aquatic environments from 
which it is transmitted to humans by an unknown mecha-
nism (28). It is hypothesized that M. ulcerans reaches the 
human dermis through a cut or wound contaminated with 
water, soil, or vegetation. M. ulcerans is a unique species 
able to produce a potent, virulence-associated toxin called 
mycolactone, which prevents phagocytosis of live organ-
isms and induces tissue destruction by its cytotoxic and im-
munosuppressive properties. Although all age groups can 
be affected, Buruli ulcer is more frequent among children 
<15 years of age; the lower limbs (which are involved 3.2× 
more often than the upper limbs) are the most frequently 
affected sites (29). The incubation period varies but is gen-
erally <3 months (4). Buruli ulcer usually starts as a single 
painless subcutaneous nodule or papule, which later moves 
to form an ulcer with undermined edges (30). Spontaneous 
healing usually takes 4–6 months and involves extensive 
scar  formation,  resulting  in  severe  deformity  with  joint 
contracture, subluxation, atrophy, or distal lymph edema 
(4). Sometimes tissue destruction may be so extensive that 
amputation is unavoidable. In addition, dissemination to 
distant sites can occur, especially in younger patients (<15 
years). Multiple lesions represent the most severe form of 
the disease; a high percentage of cases are osteomyelitis, 
often leading to amputation or even death (29). Disabilities 
are frequent, estimated for 25% to 58% of cases (31). Al-
though in M. ulcerans–endemic areas, diagnosis and treat-
ment are determined essentially by clinical appearances, 
laboratory methods are available. These methods consist 
of direct smear examination of specimens taken from the 
ulcer edge or from tissue (≈40% sensitivity); culture incu-
bated at 29°C–33°C for 6–8 weeks (≈20%–60% sensitiv-
ity); histopathologic necrosis of subcutaneous tissues and 
dermal collagen accompanied by a scant nongranuloma-
tous  inflammatory  reaction  embedding  acid-fast  bacilli 
(≈90% sensitivity) (30); and PCR, a highly sensitive test 
that can produce results within 2 days but is still confined 
to reference and research laboratories (32). Case confirma-
tion requires at least 2 positive results from the above diag-
nostic tests (33). A standardized method for susceptibility 
testing of M. ulcerans is not currently available (25). The 
main treatment for Buruli ulcer is surgery. To ensure com-
plete removal of visibly affected tissue and to prevent re-
currence, excision should include a wide margin, including 
healthy tissue. Although in early disease simple excision is 
usually curative, in advanced disease wide and traumatiz-
ing excision is needed, followed by skin grafting and long 
hospital stays. Although many antimicrobial agents have 
demonstrated excellent in vitro and in vivo activity against 
M. ulcerans clinical isolates, further studies are needed to 
assess whether experimental susceptibility data will corre-
late with clinical outcome (33). A recent report stated that 
rifampin plus streptomycin (1×/day for 4 weeks) and surgi-
cal excision inhibited the spread of infection and converted 
early lesions (nodules and plaques) from culture positive 
to culture negative (34). In edematous M. ulcerans disease, 
the most rapidly progressive form, rifampin and strepto-
mycin have demonstrated a dramatically beneficial effect. 
Other treatments (e.g., topical phenytoin powder, topical 
nitrogen oxides, and dressing plus triple-drug therapy [ri-
fampin, amikacin, and heparin]) are still being evaluated. 
M. bovis BCG vaccination appears to offer some short-term 
protection, especially against the most severe form of the 
disease (33).
Cutaneous MAC disease occurs by direct inoculation 
(trauma, surgery, injection) and is characterized by skin le-
sions such as ulceration, abscess with sinus formation, or 
erythematous plaque with a yellow crusted base. The le-
sions are indolent, with little or no lymph node reaction or 
systemic symptoms; some MAC skin infections resemble 
Lupus vulgaris infections. Diagnosis requires a high index 
of suspicion; a history of exposure to a potential source of 
infection may be suggestive. For an accurate diagnosis, 
histopathology, proper acid-fast bacilli identification, and 
susceptibility testing are needed. A combination of exci-
sion (or surgical debridement) and chemotherapy is usually 
required. Therapy is continued for 6–12 months and con-
sists of at least 3 drugs, usually clarithromycin, rifampin, 
and ethambutol. Additional therapy with amikacin is some-
times included for 6 weeks (2).
Rapidly growing mycobacteria (RGM) are a complex 
group of environmental pigmented and nonpigmented my-
cobacteria.  Their  optimal  incubation  temperatures  range 
from 25°C to 40°C, and they are characterized by a rapid 
(within 7 days) growth rate on subculture. Organisms re-
sponsible for disease in humans belong to the M. fortuitum 
group, the M. chelonae/abscessus group, and the M. smeg-
matis group; M. abscessus, M. fortuitum, and M. chelonae 
are the most common species involved in cutaneous and 
soft tissue infections. Able to survive in harsh conditions, 
these organisms produce biofilm in aquatic environments, 
mostly in piped water systems from which large clumps 
of mycobacteria are released into water and can be subse-
quently transmitted to humans (35,36). In addition, RGM 
are resistant to sterilizing agents (2% formaldehyde and 
glutaraldehyde), antiseptics (organomercurial compounds), 
and other common disinfectants (37). Clinical manifesta-
tions of RGM disease largely depend on the immunocom-
petence of the infected person. Cutaneous and soft tissue 
infections may appear as a single lesion in an immunocom-
petent person, usually after penetrating trauma or invasive 
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surgical procedure at the site of infection (M. fortuitum is 
the predominant causative agent), or they may appear as 
multiple or disseminated lesions, usually associated with 
immunosuppressive treatments (especially long-term treat-
ment with steroids) or other immunosuppressive conditions 
or concurrent illnesses (38). For the latter, M. chelonae and 
M. abscessus are the predominant causative agents. Several 
reported infections that occurred after traumatic, cosmetic, 
or other medical procedures are summarized in Table 3. 
In a large outbreak of RGM infection related to pedicures, 
the median onset of signs and symptoms was 3 weeks, but 
for some, signs and symptoms were delayed as long as 4 
months after exposure (39). Histopathologic examination 
of lesions showed suppurative granulomata and abscesses. 
Areas of necrosis were typically seen, but caseation was 
uncommon  (21).  Definitive  diagnosis  of  clinically  sus-
pected RGM soft tissue disease can be made by culture of 
organisms from drainage material, aspiration fluid, or tis-
sue biopsy sample. When NTM disease is suspected on the 
basis of clinical signs, with any patient history, laboratory 
staff should be alerted so they can use appropriate isola-
tion protocols (M. chelonae and some strains of M. absces-
sus are relatively heat intolerant and can be recovered by 
primary isolation at 30°C). Identification of RGM at the 
species level is of utmost importance because treatment 
regimens and consequently clinical outcome are strongly 
species  related.  Proper  identification  involves  molecular 
techniques (22) coupled with a few traditional biochemical 
and phenotypic tests (use of the carbohydrates citrate, man-
nitol, inositol, and sorbitol; tolerance to 5% NaCl; nitrate 
reduction;  iron  uptake;  and  3-day  arylsulfatase  activity) 
(35). Susceptibility testing performed by the broth microdi-
lution technique (25) is essential for choosing the most ef-
fective drug therapy and monitoring for the development 
of mutational drug resistance (2). Most experts recommend 
the use of specific antimicrobial drugs, given in combina-
tion to avoid the emergence of drug resistance. Treatment 
for the M. fortuitum group may include amikacin, cefoxi-
tin, ciprofloxacin, the newer quinolones gatifloxacin and 
moxifloxacin, sulfonamides, and imipenem. Some degree 
of  susceptibility  to  doxycycline  and  clarithromycin  has 
been reported. M. abscessus strains are usually suscepti-
ble to amikacin, cefoxitin, imipenem, clarithromycin, and 
azithromycin; M. chelonae are usually susceptible to amika-
cin, imipenem, tobramycin, clarithromycin, and sometimes 
linezolid. Clarithromycin is generally the drug of choice 
for localized disease caused by M. chelonae and M. absces-
sus (5,35). The duration of therapy is usually 4 months for 
mild disease and 6 months for severe disease. Surgery is an 
important complementary tool for treating these infections, 
depending on disease severity and location.
Laboratory Diagnosis
Of all the currently described mycobacterial species, 
≈60% have caused human diseases. For this reason, mod-
ern techniques for faster culture, identification, and drug 
susceptibility testing are urgently needed in mycobacteri-
ology laboratories (22,25). In addition to the collection of 
high-quality specimens, timely diagnosis of NTM disease 
requires regular communication of clinical suspicion to the 
laboratory staff because optimal recover of some fastidi-
ous species requires additional tasks. Routine techniques 
include microscopy and culture; the latter should be per-
formed by using both liquid and solid media incubated at 
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Table 3. Skin and soft tissue infections caused by rapidly growing mycobacteria 
Type of infection or procedure  Mycobacterium spp.  Clinical findings 
Posttraumatic wound infections  M. fortuitum, M. chelonae, M. abscessus, 
M. wolinskyi, M. goodii, M. porcinum
Subcutaneous abscesses, cellulitis 
Pedicures  M. fortuitum, M. chelonae, M. mageritense Furunculosis
Subcutaneous, intraarticular, or 
periarticular Injections 
M. chelonae, M. abscessus Subcutaneous abscesses, painful nodules, 
multiple sinus tracts, joint infections, fever, 
chills after injection 
Acupuncture M. abscessus, M. chelonae, M. 
nonchromogenicum
Erythematous papules, nodules, ulcerative 
lesions, abscesses, confluent plaques, draining 
sinus tracts with discharge, wrist tenosynovitis 
Cardiac surgery  M. peregrinum, M. fortuitum, M. fortuitum
(third biovariant) complex, M. wolinskyi, M. 
goodii, M. abscessus
Sternal wound infection, endocarditis 
Cosmetic surgery or other surgical 
procedures: liposuction, liposculpture, 
face lift, breast lift (reduction 
augmentation), silicon injection 
M. fortuitum, M. chelonae, M. chelonae, M. 
porcinum, M. wolinskyi, M. goodii
Erythema, tenderness, nodules, skin 
induration, subcutaneous or deep-tissue 
abscesses, fever, malaise, multiple abscesses 
along original suction tracts, draining sinus 
tracts, local pain, swelling 
Nipple piercing  M. fortuitum, M. abscessus Asymptomatic nodules, tender nodules 
Implanted with prosthetic material  M. abscessus, M. goodii Abscesses
Pacemaker placement  M. fortuitum, M. abscessus, M. wolinskyi Abscesses
Peritoneal dialysis catheter  M. abscessus AbscessesExtrapulmonary Infections and NTM
different  temperatures  (22).  Although  optimal  recovery 
for  most  clinically  relevant  mycobacteria  is  obtained  at 
35C°–37C°, some species (M. hemophilum, M. marinum, 
M. ulcerans and some species of RGM) require a lower 
incubation temperature to grow. For this reason, all clinical 
specimens that may harbor the above species (skin, syn-
ovial fluid, and bone) should be cultured at 28C°–30C° and 
at 35C°–37C°. Use of conventional biochemical and phe-
notypic tests for the identification of NTM is currently dis-
couraged; more rapid and specific methods are favored, in-
cluding high-performance liquid chromatography analysis 
of mycolic acids and commercial molecular assays. These 
may use either in-solution hybridization (Accuprobe, Gen-
Probe Inc., San Diego, CA, USA) or solid-format reverse-
hybridization  assays  (line  probe  assays)  (22).Both  tech-
niques are specific, but the latter (in which amplification 
precedes hybridization) is more sensitive, enabling iden-
tification in the early stage of bacterial growth. Finally, 
gene (16S rDNA) sequencing is required for those species 
that cannot be identified by the above systems (22). Care-
ful strategies should be recommended for using 16S rDNA 
sequence analysis databases because public databases may 
have wrong sequences and commercial ones tend to be un-
derdeveloped and outdated (23,40).
Conclusion
Although NTM cause a broad spectrum of human dis-
ease, data on incidence of NTM infections are still lacking, 
mainly because of the absence of systematic epidemiologic 
studies, standard case definitions, and accurate mycobacte-
rial identification. Furthermore, nonspecific clinical mani-
festations,  lack  of  familiarity  with  these  infections,  and 
inadequate laboratory services make definitive diagnosis 
of NTM diseases often delayed or even impossible. Cor-
relation of in vitro susceptibility testing with the clinical 
outcome, composition and duration of treatment regimens, 
and use of surgery or other therapeutic approaches are still 
undefined for most NTM species involved in human dis-
eases. Laboratory research and multicenter controlled trials 
are needed to improve diagnosis and treatment of extrapul-
monary NTM infections.
Dr Piersimoni is a clinical microbiology consultant at the 
United Hospitals, Ancona, Italy. His primary research interest 
focuses on diagnostic and clinical aspects of mycobacterial infec-
tions.
Dr Scarparo is a medical microbiologist and head of the 
Clinical Microbiology Laboratory at the Santa Maria della Mise-
ricordia University Hospital, Udine, Italy. His primary interests 
include the epidemiology, diagnosis, and treatment of mycobacte-
rial infections.
References 
  1.   Falkinham JO. Epidemiology of infection by nontuberculosis myco-
bacteria. Clin Microbiol Rev. 1996;9:177–215.
  2.   Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, 
Gordin F. An official ATS/IDSA statement: diagnosis, treatment, and 
prevention of nontuberculous mycobacterial disease. Am J Respir 
Crit  Care  Med.  2007;175:367–416.  DOI:  10.1164/rccm.200604-
571ST
  3.   Marchevsky AM, Damsker B, Green S, Tepper S. The clinicopatho-
logical spectrum of nontuberculous mycobacterial osteoarticular in-
fections. J Bone Joint Surg Am. 1985;67:925–9.
  4.   Dobos  KM,  Quinn  FD, Ashford  DA,  Horsburgh  CR,  King  CH. 
Emergence of a unique group of necrotizing mycobacterial diseases. 
Emerg Infect Dis. 1999;5:367–78.
  5.   De Groote MA, Huitt G. Infections due to rapidly growing myco-
bacteria. Clin Infect Dis. 2006;42:1756–63. DOI: 10.1086/504381
  6.   Lai KK, Stottmeier KD, Sherman IH, McCabe WR. Mycobacte-
rial cervical lymphadenopathy. Relation of etiologic agent to age. 
JAMA. 1984;251:1286–8. DOI: 10.1001/jama.251.10.1286
  7.   Lindeboom JA, Prins JM, Bruijnesteijn van Coppenraet ES, Linde-
boom R, Kuijper EJ. Cervicofacial lymphadenitis in children caused 
by Mycobacterium haemophilum. Clin Infect Dis. 2005;41:1569–75. 
DOI: 10.1086/497834
  8.   Tortoli  E.  Impact  of  genotypic  studies  on  mycobacterial  tax-
onomy: the new mycobacteria of the 1990s. Clin Microbiol Rev. 
2003;16:319–54. DOI: 10.1128/CMR.16.2.319-354.2003
  9.   Ellison E, Lapuerta P, Martin SE. Fine needle aspiration diagnosis of 
mycobacterial lymphadenitis. Sensitivity and predictive value in the 
United States. Acta Cytol. 1999;43:153–7.
10.   Lindeboom JA, Kuijper EJ, Prins JM, Bruijnesteijn van Coppenraet 
ES, Lindeboom R. Tuberculin skin testing is useful in the screen-
ing for nontuberculous mycobacterial cervicofacial lymphadenitis in 
children. Clin Infect Dis. 2006;43:1547–51. DOI: 10.1086/509326
11.   Lindeboom JA, Kuijper EJ, Prins JM, Bruijnesteijn van Coppenraet 
ES,  Lindeboom  R,  Prins  JM.  Surgical  excision  versus  antibiotic 
treatment for nontuberculous mycobacteria cervical lymphadenitis 
in children: a multicenter, randomized, controlled trial. Clin Infect 
Dis. 2007;44:1057–64. DOI: 10.1086/512675
12.   Petitjean G, Fluckiger U, Schären S, Laifer G. Vertebral osteomyeli-
tis caused by non-tuberculous mycobacteria. Clin Microbiol Infect. 
2004;10:951–3. DOI: 10.1111/j.1469-0691.2004.00949.x
13.   Elsayed  S,  Read  R.  Mycobacterium  haemophilum  osteomyelitis: 
case report and review of the literature. BMC Infect Dis. 2006;6:70. 
DOI: 10.1186/1471-2334-6-70
14.   Zenone T, Boibieux A, Tigaud S, Fredenucci JF, Vincent V, Chidiac C, 
et al. Non-tuberculous mycobacterial tenosynovitis: a review. Scand 
J Infect Dis. 1999;31:221–8. DOI: 10.1080/00365549950163482
15.   Theodorou DJ, Theodorou SJ, Kakitsubata Y, Sartoris DJ, Resnick 
D. Imaging characteristics and epidemiological features of atypical 
mycobacterial infections involving the musculoskeletal system. AJR 
Am J Roentgenol. 2001;176:341–9.
16.   Casal M, Casal MM; Spanish Group of Mycobacteriology. Multi-
center study of incidence of Mycobacterium marinum in humans in 
Spain. Int. J Tuberc Lung Dis. 2001;5:197–9. 
17.   Hess CL, Wolock BS, Murphy MS. Mycobacterium marinum infec-
tions of the upper extremity. Plast Reconstr Surg. 2005;115:55e–9e. 
DOI: 10.1097/01.PRS.0000153197.64808.B9 
18.   Edelstein H. Mycobacterium marinum skin infections. Report of 31 
cases and review of the literature. Arch Intern Med. 1994;154:1359–
64. DOI: 10.1001/archinte.154.12.1359
19.   Aubry A, Chosidow O, Caumes E, Robert J, Cambau E. Sixty-three 
cases of Mycobacterium marinum infection: clinical features, treat-
ment, and antibiotic susceptibility of causative isolates. Arch Intern 
Med. 2002;162:1746–52. DOI: 10.1001/archinte.162.15.1746
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 9, September 2009  1357 SYNOPSIS
20.   Ang  P,  Rattana-Apiromyakij  N,  Goh  CL.  Retrospective  study 
of  Mycobacterium  marinum  skin  infections.  Int  J  Dermatol. 
2000;39:343–7. DOI: 10.1046/j.1365-4362.2000.00916.x
21.   Bartralot R, Pujol RM, García-Patos V, Sitjas D, Martín-Casabona 
N, Coll P, et al. Cutaneous infections due to nontuberculous myco-
bacteria: histopathological review of 28 cases. Comparative study 
between lesions observed in immunosuppressed patients and normal 
hosts. J Cutan Pathol. 2000;27:124–9. DOI: 10.1034/j.1600-0560
.2000.027003124.x
22.   Clinical and Laboratory Standards Institute. Laboratory detection 
and identification of mycobacteria: approved guideline. CLSI docu-
ment M48-A. Wayne (PA): The Institute; 2008.
23.   Cloud JL, Neal H, Rosenberry R, Turenne CY, Jama M, Hillyard 
DR, et al. Identification of Mycobacterium spp. by using a com-
mercial 16S ribosomal DNA sequencing kit and additional sequenc-
ing  libraries.  J  Clin  Microbiol.  2002;40:400–6.  DOI:  10.1128/
JCM.40.2.400-406.2002
24.   Bråbäck M, Riesbeck K, Forsgren A. Susceptibilities of Mycobacte-
rium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, 
moxifloxacin, telithromycin, and quinupristin-dalfopristin (Syner-
cid)  compared  to  its  susceptibilities  to  reference  macrolides  and 
quinolones. Antimicrob Agents Chemother. 2002;46:1114–6. DOI: 
10.1128/AAC.46.4.1114-1116.2002
25.   National Committee for Clinical Laboratory Standards. Susceptibil-
ity testing of mycobacteria, nocardia, and other aerobic actinomycet-
es. Approved standard M24-A. Wayne (PA): The Committee; 2003.
26.   World Health Organization. Buruli ulcer disease. Mycobacterium 
ulcerans infection: an overview of reported cases globally. Wkly 
Epidemiol Rec. 2004;79:194–200.
27.   Amofah  G,  Bonsu  F,  Tetteh  C,  Okrah  J, Asamoa  K.  Buruli  ul-
cer in Ghana: results of a national case search. Emerg Infect Dis. 
2002;8:167–70.
28.   Marsollier  L,  Severin  T, Aubry  J,  Merritt  RW,  Saint Andre  JP, 
Legras P, et al. Aquatic snails, passive hosts of Mycobacterium ul-
cerans. Appl Environ Microbiol. 2004;70:6296–8. DOI: 10.1128/
AEM.70.10.6296-6298.2004
29.   Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, Scott 
JT, et al. Mycobacterium ulcerans disease: role of age and gender 
in incidence and morbidity. Trop Med Int Health. 2004;9:1297–304. 
DOI: 10.1111/j.1365-3156.2004.01339.x
30.   Guarner J, Bartlett J, Whitney EA, Raghunathan PL, Stienstra Y, 
Asamoa K, et al. Histopathologic features of Mycobacterium ulcer-
ans infection. Emerg Infect Dis. 2003;9:651–6.
31.   Ellen DE, Stienstra Y, Teelken MA, Dijkstra PU, van der Graaf WT, 
van der Werf TS. Assessment of functional limitations caused by 
Mycobacterium ulcerans infections: towards a Buruli ulcer func-
tional limitation score. Trop Med Int Health. 2003;8:90–6. DOI: 
10.1046/j.1365-3156.2003.00976.x
32.   Ross BC, Marino L, Oppedisano F, Edwards R, Robins-Browne RM, 
Johnson PD. Development of a PCR assay for rapid diagnosis of 
Mycobacterium ulcerans infection. J Clin Microbiol. 1997;35:1696–
700.
33.   Wansbrough-Jones  M,  Phillips  R.  Buruli  ulcer:  emerging  from 
obscurity.  Lancet.  2006;367:1849–58.  DOI:  10.1016/S0140-6736 
(06)68807-7
34.   Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, Phillips 
R, et al. Efficacy of the combination rifampin-streptomycin in pre-
venting growth of Mycobacterium ulcerans in early lesions of Buruli 
ulcer in humans. Antimicrob Agents Chemother. 2005;49:3182–6. 
DOI: 10.1128/AAC.49.8.3182-3186.2005
35.   Brown-Elliott  BA, Wallace  RJ  Jr.  Clinical  and  taxonomic  status 
of pathogenic nonpigmented late-pigmenting rapidly growing my-
cobacteria.  Clin  Microbiol  Rev.  2002;15:716–46.  DOI:  10.1128/
CMR.15.4.716-746.2002
36.   Hall-Stoodley L, Stoodley P. Biofilm formation and dispersal and the 
transmission of human pathogens. Trends Microbiol. 2005;13:7–10. 
DOI: 10.1016/j.tim.2004.11.004
37.   Wallace RJ Jr, Brown BA, Griffith DE. Nosocomial outbreaks/pseu-
do-outbreaks caused by nontuberculous mycobacteria. Annu Rev 
Microbiol. 1998;52:453–90. DOI: 10.1146/annurev.micro.52.1.453
38.   Uslan DZ, Kowalski TJ, Wengenack LW, Virk A, Wilson JW. Skin 
and soft tissue infections due to rapidly growing mycobacteria. Arch 
Dermatol. 2006;142:1287–92. DOI: 10.1001/archderm.142.10.1287
39.   Winthrop KL, Abrams M, Yakrus M, Schwartz I, Ely J, Gillies D, 
et al. An outbreak of mycobacterial furunculosis associated with 
footbaths at a nail salon. N Engl J Med. 2002;346:1366–71. DOI: 
10.1056/NEJMoa012643
40.   Turenne CY, Tschetter L, Wolfe J, Kabani A. Necessity of quality-
controlled 16S rRNA gene sequence databases: identifying nontu-
berculous Mycobacterium species. J Clin Microbiol. 2001;39:3637–
48. DOI: 10.1128/JCM.39.10.3638-3648.2001
Address for correspondence: Claudio Piersimoni, Department of Clinical 
Microbiology, United Hospitals, via Conca 71, I-60020 Ancona, Italy; 
email: piersim@tin.it
1358  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 9, September 2009